AORT (Artivion) YoY EBITDA Growth: -86.91% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AORT Artivion Inc AORT
80 GF Score
Price $23.67
GF Value $29.21
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Artivion YoY EBITDA Growth?

Artivion AORT +0.17% 80 YoY EBITDA Growth is -86.91% as of Jun. 2026. GuruFocus rates AORT with a GF Score™ of 80/100 and a GF Value™ of $29.21 (Modestly Undervalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Artivion's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -86.91%.

Artivion's EBITDA per Share for the three months ended in Jun. 2026 was $0.05.

Artivion YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Artivion's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artivion YoY EBITDA Growth Chart

Artivion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.23 -4.10 4.43 85.61 10.61

Artivion Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.86 22.08 2,861.54 -5.47 -86.91
AORT
80GF Score
Artivion Inc AORT
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artivion YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Artivion's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(1.355-1.225)/ | 1.225 |
=10.61 %

Artivion's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.047-0.359)/ | 0.359 |
=-86.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -86.91% mean?
Artivion (AORT) has a YoY EBITDA Growth of -86.91% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Artivion and its competitors.
Is Artivion's YoY EBITDA Growth too high?
Artivion's current YoY EBITDA Growth is -86.91%. Overall, Artivion has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Artivion's YoY EBITDA Growth compare to IART and PRCT?
Artivion's YoY EBITDA Growth of -86.91% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Artivion and its competitors. Artivion's current YoY EBITDA Growth is -86.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artivion stock overvalued right now?
Based on GuruFocus' analysis, Artivion (AORT) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.21, compared to a current price of $23.67 — trading 19% below its estimated fair value. The current YoY EBITDA Growth is -86.91%. Artivion's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Artivion (AORT), the current YoY EBITDA Growth is -86.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Artivion (AORT) Overvalued in 2026?

Based on GuruFocus' analysis, Artivion stock appears to be undervalued. The current stock price of $23.67 is trading 19% below its estimated GF Value™ of $29.21. GuruFocus considers Artivion to be Modestly Undervalued.

Key valuation signals for AORT:

  • YoY EBITDA Growth: -86.91%
  • GF Value™: $29.21 vs. price of $23.67 (19% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the AORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Artivion Business Description

Other Exchanges CYL:Germany
Address 1655 Roberts Boulevard North West, Kennesaw, GA, USA, 30144
Artivion Inc, formerly CryoLife, is a medical device company that develops and manufactures cardiac and vascular surgical products, primarily focused on the aorta. Its product portfolio includes aortic stent grafts, surgical sealants and adhesives, On-X mechanical heart valves, and implantable human tissues such as aortic and pulmonary heart valves and patches processed through its preservation services. The company serves cardiac and vascular surgeons and hospitals, operating through two segments: Medical Devices and Preservation Services. Artivion sells across North America, Europe, the Middle East and Africa, Latin America, and Asia-Pacific, with North America generating the largest share of revenue. Revenue comes from product sales of devices and tissue implants, supplemented by preservation service fees. The company is headquartered in Kennesaw, Georgia.
80GF Score

Get the complete analysis for AORT

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.67
Price
$29.21
GF Value